Hilgers distinguishes isomolecular hormones -- molecules structurally identical to endogenous estradiol and progesterone -- from heteromolecular artimones, his term for synthetic analogues such as medroxyprogesterone acetate, norethindrone, and ethinyl estradiol, which differ in receptor binding, metabolic pathways, and systemic effects. NaProTECHNOLOGY restricts hormone therapy to isomolecular compounds administered in cycle-synchronized, physiologic doses because artimones suppress the hypothalamic-pituitary-ovarian axis, mask underlying pathology, and produce non-physiologic metabolite profiles incompatible with a restorative reproductive medicine approach.
difference between bioidentical and synthetic progesterone, isomolecular hormone vs heteromolecular artimone NaProTechnology, does medroxyprogesterone acetate increase heart disease risk, HERS trial MPA cardiovascular harm estrogen, natural progesterone breast cancer protection progesterone deficiency, progesterone receptor PR-A PR-B isoforms function, why does basal body temperature rise after ovulation progesterone, vaginal progesterone first uterine pass effect endometrium
Hilgers et al. 2004, Hilgers 2004
Cite this article
Hilgers, T. W. (2004). Chapter 26: Isomolecular Hormones vs Heteromolecular Artimones. The Medical and Surgical Practice of NaProTECHNOLOGY, 307-334.
Hilgers TW. Chapter 26: Isomolecular Hormones vs Heteromolecular Artimones. The Medical and Surgical Practice of NaProTECHNOLOGY. 2004:307-334.
Hilgers, T. W. "Chapter 26: Isomolecular Hormones vs Heteromolecular Artimones." The Medical and Surgical Practice of NaProTECHNOLOGY, 2004, pp. 307-334.
Thomas W. Hilgers, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Medical protocols in NaProTECHNOLOGY are cycle-phase-targeted regimens — covering ovulation induction, luteal phase hormonal support, hyperprolactinemia management, thyroid optimization, and pre-conceptual supplementation — derived from the biomarker-defined diagnosis rather than empirical stimulation. Consolidating these protocols in a single reference enables practitioners to apply evidence-based, individualized treatment sequences that address root hormonal pathology while supporting natural conception.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Structured postoperative management following PEARS procedures addresses wound care, pain control, early ambulation, hormonal support, and surveillance for complications including bleeding, infection, urinary injury, and bowel complications. NaProTECHNOLOGY postoperative protocols integrate CrMS-guided hormonal monitoring to optimize the healing environment and time the resumption of targeted fertility treatment.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Postpartum depression in susceptible women is linked to abrupt postpartum progesterone withdrawal following the high-progesterone state of pregnancy, particularly in those with prior PMS, luteal phase defects, or recurrent miscarriage, and NaProTECHNOLOGY evaluates this through serum progesterone, thyroid function, and prolactin assessment in the postpartum period. Treatment uses bioidentical progesterone -- preferably intramuscular for reliable absorption -- with serum levels monitored every two weeks for dose titration, and once cycles resume, dosing is resynchronized to the CrMS Peak day; Hilgers reports no increase in congenital anomalies in over 2,000 progesterone-supported pregnancies in the Pope Paul VI Institute series.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Cooperative progesterone and estrogen replacement therapy administers bioidentical hormones in precise synchrony with the woman's CrMS-identified Peak day -- beginning progesterone at P+2 or P+3 and continuing through the luteal phase -- to augment deficient corpus luteum output rather than override the cycle with suppressive dosing. Serial serum progesterone across post-Peak days guides dose titration, and the approach is applied to luteal phase deficiency, recurrent miscarriage, premenstrual syndrome, and postpartum depression while preserving ovulatory function and fertility.